Cidara Therapeutics, Inc.

NasdaqCM:CDTX Stock Report

Market Cap: US$203.2m

Cidara Therapeutics Management

Management criteria checks 3/4

Cidara Therapeutics' CEO is Jeff Stein, appointed in Jan 2014, has a tenure of 11.08 years. total yearly compensation is $1.56M, comprised of 38.1% salary and 61.9% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 3.8 years and 4.1 years respectively.

Key information

Jeff Stein

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage38.1%
CEO tenure11.1yrs
CEO ownership0.7%
Management average tenure3.8yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Mar 14
We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara spikes on $11M milestone payment from partner Mundipharma

Oct 04

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Sep 13

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17
Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17
Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04
Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

CEO Compensation Analysis

How has Jeff Stein's remuneration changed compared to Cidara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$124m

Jun 30 2024n/an/a

-US$112m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$2mUS$594k

-US$25m

Sep 30 2023n/an/a

-US$34m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$1mUS$566k

-US$22m

Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$2mUS$566k

-US$42m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$1mUS$542k

-US$75m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$47m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$526k

-US$41m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$1mUS$501k

-US$69m

Compensation vs Market: Jeff's total compensation ($USD1.56M) is about average for companies of similar size in the US market ($USD1.39M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.

CEO

Jeff Stein (69 yo)

11.1yrs

Tenure

US$1,558,544

Compensation

Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...

Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Stein
President11.1yrsUS$1.56m0.67%
$ 1.4m
Shane Ward
COO & Corporate Secretary3.5yrsUS$929.86k0.047%
$ 95.4k
Taylor Sandison
Chief Medical Officer8.4yrsUS$884.09k0.12%
$ 237.7k
Kevin Forrest
Founder & Chief Strategy Officerno dataUS$613.24kno data
Preetam Shah
CFO & Principal Accounting Officer3.4yrsUS$683.71k0.069%
$ 139.6k
Allison Lewis
Senior Vice President of People & Culture4.1yrsno datano data
Leslie Tari
Chief Scientific Officer5.9yrsUS$1.39m0.077%
$ 156.5k
Nicole Davarpanah
Interim Chief Medical Officer and Senior VP of Translational Research & Development1.5yrsno datano data
Jim Beitel
Chief Business Officerless than a yearno datano data

3.8yrs

Average Tenure

52yo

Average Age

Experienced Management: CDTX's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Stein
President11.1yrsUS$1.56m0.67%
$ 1.4m
Daniel Burgess
Independent Chairman of the Board10.8yrsUS$126.84k0.0014%
$ 2.8k
Theodore Schroeder
Independent Director10.8yrsUS$98.84k0%
$ 0
Rick Bright
Member of Scientific Advisory Boardless than a yearno datano data
Frederick Hayden
Member of the Scientific Advisory Board4.6yrsno datano data
Bonnie Bassler
Independent Director4.1yrsUS$86.84k0.00014%
$ 284.5
Carin Canale-Theakston
Independent Director4.1yrsUS$82.34k0%
$ 0
Chrysa Mineo
Independent Director6.9yrsUS$91.34k0%
$ 0
Ryan Spencer
Independent Directorless than a yearno datano data
James Merson
Independent Directorless than a yearno datano data
Mario Barro
Member of Scientific Advisory Boardless than a yearno datano data
Philip Krause
Member of Scientific Advisory Boardless than a yearno datano data

4.1yrs

Average Tenure

62yo

Average Age

Experienced Board: CDTX's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 06:02
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cidara Therapeutics, Inc. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Timothy ChiangBTIG
Chiara RussoCantor Fitzgerald & Co.
Louise ChenCantor Fitzgerald & Co.